AI Article Synopsis
- The study evaluated a group stabilisation intervention for PTSD patients on the waitlist for individual therapy, aiming to ease prolonged suffering due to extended wait times in NHS services.
- Fifty-eight patients participated, and the group therapy was found to be both feasible and acceptable, resulting in medium to large reductions in PTSD symptoms and minimal deterioration in anxiety and depression.
- Preliminary evidence suggests that attending psychoeducational group therapy can be beneficial while waiting for individualized trauma-focused treatment.
Article Abstract
Background: Large numbers of people showing complex presentations of post-traumatic stress disorder (PTSD) in the NHS Talking Therapies services routinely require multi-faceted and extended one-to-one National Institute of Clinical Excellence (NICE) recommended treatment approaches. This can lead to longer waits for therapy and prolong patient suffering. We therefore evaluated whether a group stabilisation intervention delivered to patients on the waitlist for individual trauma-focused psychological treatment could help address this burden.
Aims: The study aimed to ascertain a trauma-focused stabilisation group's acceptability, feasibility, and preliminary clinical benefit.
Method And Results: Fifty-eight patients with PTSD waiting for trauma-focused individual treatment were included in the study. Two therapists delivered six 5-session groups. The stabilisation group was found to be feasible and acceptable. Overall, PTSD symptom reduction was medium to large, with a Cohen's of .77 for intent-to-treat and 1.05 for per protocol analyses. Additionally, for depression and anxiety, there was minimal symptom deterioration.
Conclusions: The study provided preliminary evidence for the acceptability, feasibility and clinical benefit of attending a psychoeducational group therapy whilst waiting for one-to-one trauma therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1352465823000486 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Wearable technology in inflammatory bowel disease: current state and future direction.
Expert Rev Med Devices
January 2025
Division of Gastroenterology, P.D Hinduja Hospital, Mumbai, India.
Introduction: Wearables are electronic devices worn on the body to collect health data. These devices, like smartwatches and patches, use sensors to gather information on various health parameters. This review highlights current use and the potential benefit of wearable technology in patients with inflammatory bowel disease (IBD).
View Article and Find Full Text PDFUpdates on Methods for Body Composition Analysis: Implications for Clinical Practice.
Curr Obes Rep
January 2025
Metabolism and Body Composition, Pennington Biomedical Research Center, Baton Rouge, LA, 70808, USA.
Background: Recent technological advances have introduced novel methods for measuring body composition, each with unique benefits and limitations. The choice of method often depends on the trade-offs between accuracy, cost, participant burden, and the ability to measure specific body composition compartments.
Objective: To review the considerations of cost, accuracy, portability, and participant burden in reference and emerging body composition assessment methods, and to evaluate their clinical applicability.
Tocilizumab alleviated lipopolysaccharide-induced acute lung injury by improving PI3K/AKT pathway.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Clinical Medicine, Fujian Medical University, Fuzhou, 350000, China.
Acute lung injury (ALI) is a severe inflammatory condition of the respiratory system, associated with high morbidity and mortality. This study investigates the therapeutic potential of tocilizumab (TZ), an IL-6 receptor inhibitor, in mitigating lipopolysaccharide (LPS)-induced ALI by modulating the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway. An ALI model was established using LPS induction.
View Article and Find Full Text PDFBruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn.
J Neurol
January 2025
Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK.
The first of several phase 3 trials examining efficacy in relapsing MS has not been able to demonstrate a significant benefit and has also raised important safety concerns. More results are on their way and it will be important to understand whether the safety signals identified are drug- or class-specific and whether other BTKi also fail to reach their endpoints for relapsing MS. However, as reported in preliminary data for another BTKi, it may be that they will have more of a role in progressive disease as hinted by the unraveling of relevant molecular mechanisms and pathways.
View Article and Find Full Text PDFEthnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Clin Transl Oncol
January 2025
Federal University of Pará, Belém, Pará, 66073-005, Brazil.
Background: The benefit of treatment with tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR-TKI) for lung adenocarcinoma (ADC), stratified by ethnicity, has not yet been fully elucidated.
Methods: We searched PubMed, Embase, and Cochrane databases for studies that investigated EGFR-TKI for lung ADC. We computed hazard ratios (HRs) or risk ratios (RRs) for binary endpoints, with 95% confidence intervals (CIs).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!